|
ISPOR 8th Annual European Congress
6-8
November 2005, Palazzo Degli Affari, Florence, Italy
|
|
POSTER PRESENTATIONS - SESSION I |
|
Sunday, 6 November
2005: 12:00-20:00 |
|
|
|
|
|
|
METHODS & CONCEPTS |
|
|
PMC1 |
|
DEVELOPMENT OF A NEW QUESTIONNAIRE TO MEASURE
SATISFACTION WITH TREATMENT WITH MEDICINES (SATMED-Q)
Ruíz M1, Pardo A1, Rejas J2,
Soto J2, Villasante F3, Aranguren J4
1College of Psychology, Universidad Autónoma de Madrid, Ciudad
Universitaria de Cantoblanco, Madrid, Spain; 2 Pfizer Spain,
Alcobendas, Madrid, Spain; 3 Primary Health Center Horcasitas,
Madrid, Madrid, Spain; 4 Clínica Madrid, Fuenlabrada, Madrid,
Spain |
|
|
PMC2 |
|
REVIEW OF THE ACTIVITIES OF THE ISOQOL TRANSLATION
AND CULTURAL ADAPTATION (TCA) SPECIAL INTEREST GROUP (SIG)
Acquadro C
Mapi Research Trust, Lyon, Rhone, France |
|
|
PMC3 |
|
INTERNATIONAL VARIATION IN CLINICAL INJURY
INCIDENCE: REAL OR ARTIFICIAL DIFFERENCES?
Polinder S1, Meeding WJ1, Lyons RA2,
Toet H3, Mulder S3, Van Beeck EF1
1ErasmusMC, Rotterdam, Netherlands; 2 University of
Wales Swansea, Swansea, United Kingdom; 3 Consumer Safety
Institute, Amsterdam, Netherlands |
|
|
PMC4 |
|
WITHDRAWN |
|
|
PMC5 |
|
A STANDARD SET OF UNIT COSTS FOR GERMANY
Schweikert B1, Hessel FP2, Hansmeier T3,
Wasem J2, Seitz R4, Krauth C5
1Ludwig-Maximilians-University, Munich, Germany; 2
University of Duisburg-Essen, Essen, NRW, Germany; 3 Federal
Insurance Institution for Salaried Employees, Berlin, Germany; 4
BKK Landesverband Bayern (Association of Company Sickness Funds), Munich,
Germany; 5 Hannover Medical School, Hannover, Germany |
|
|
PMC6 |
|
AFFORDABLE BOOTSTRAPS? EVALUATING FREEWARE OPTIONS
FOR ANALYZING INCREMENTAL COST EFFECTIVENESS DATA
McGhan W, Gandhi P, Ruparel P, Peterson A
University of the Sciences, Philadelphia, PA, USA |
|
|
PMC7 |
|
WITHDRAWN |
|
|
PMC8 |
|
ESTIMATING COSTS AT THE FAMILY LEVEL
Boudreau DM1, Bonomi AE1, Fishman PA1,
Meenan RT2
1Group Health Cooperative, Seattle, WA, USA; 2
Kaiser Permanente, Portland, OR, USA |
|
|
PMC9 |
|
THE OPTIMAL COST-EFFECTIVENESS RATIO THRESHOLD IN
CASE OF CO-MORBIDITIES
Jakubczyk MK1, Niewada M2, Kowalik E3
1Warsaw School of Economics, Warsaw, Poland; 2
Medical University of Warsaw, Warsaw, Poland; 3 Institute of
Cardiology, Warsaw, Poland |
|
|
PMC10 |
|
WITHDRAWN |
|
|
PMC11 |
|
DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK
ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A U.S. MEDICAID
POPULATION
Cantrell CR1,
Martin BC2
1GlaxoSmithKline, RTP, NC, USA; 2 University of
Arkansas for Medical Sciences, Little Rock, AR, USA |
|
|
PMC12 |
|
PHARMACOECONOMIC ASPECTS OF THE ADMINISTRATIVE
REFORMS IN PHARMACEUTICAL SECTORS OF REPUBLIC HEALTH DEPARTMENTS IN
MONTENEGRO
Tomic Z1, Sabo A1, Bralic R2,
Glomazic Z2, Mikov M1
1Medical Faculty, Novi Sad, Vojvodina, Serbia and Montenegro;
2 Republic Health Department, Podgorica, -, Serbia and
Montenegro |
|
|
PMC13 |
|
ECONOMIC IMPACT OF HOSPITAL MALNUTRITION
Ethgen O1, Spaepen E2, Moeremans K2,
Annemans L2
1University of Liège, Liège, Belgium; 2 IMS Health,
Brussels, Belgium |
|
|
PMC14 |
|
POPULATION KNOWLEDGE: AN APPROACH TO CLASSIFY A
GENERAL POPULATION ACCORDING TO LIFESTYLE, HEALTH BEHAVIOUR AND ATTITUDE
Auray JP1, Nicoloyannis N2, Dinet J3
1Université Claude Bernard Lyon 1, Villeurbanne, France;
2 Université Lumière Lyon 2, Bron, France; 3
Sanofi-Aventis France, Paris, France |
|
|
PMC15 |
|
DIRECT AND INDIRECT COSTS AND EFFECTS IN
COST-EFFECTIVENESS ANALYSIS OF PREVENTION: A DYNAMIC MODELLING ANALYSIS
Van Baal P, Feenstra T, Hoogenveen R, de Wit G
National Institute of Public Health and the Environment, Bilthoven,
Netherlands |
|
|
PMC16 |
|
WITHDRAWN |
|
|
PMC17 |
|
RASCH ANALYSIS OF THE FATIGUE IMPACT SCALE
Meads DM1, Hampson NE1, Fisk JD2,
McKenna SP1, Doward LC1, Mayo KW3
1Galen Research, Manchester, Manchester, United Kingdom;
2 Dalhousie University, Halifax, Nova Scotia, Canada; 3
Novartis Pharma AG, Basel, Basel, Switzerland |
|
|
PMC18 |
|
PSYCHOMETRIC PROPERTIES OF A TOUCH SCREEN
COMPUTER-BASED VERSION OF THE SF-36
Ramachandran S1, Taber T2, Coons SJ1
1University of Arizona, Tucson, AZ, USA; 2 Assist
Technologies, Scottsdale, AZ, USA |
|
|
PMC19 |
|
HOW LONG AGO…?: ASSESSING PATIENT ADHERENCE TO
SPECIFIED QUESTIONNAIRE RECALL PERIODS
Coyne KS, Brewster-Jordan J
The MEDTAP Institute at UBC, Bethesda, MD, USA |
|
|
PMC20 |
|
INDIRECT COMPARISON (OR COMMON-COMPARATOR) METHODS
FOR META-ANALYSIS OF SUMMARY DATA
Fitzgerald P, LeReun C, Aristides M
M-TAG, A division of IMS Health Economics and Outcomes Research, London,
United Kingdom |
|
|
PMC21 |
|
EVALUATING THE DIFFERENCE BETWEEN AVERAGE WHOLESALE
PRICE AND WHOLESALE ACQUISITION COST FOR PHARMACEUTICALS IN THE UNITED
STATES
Malone DC, Mahmood M
University of Arizona College of Pharmacy, Tucson, AZ, USA |
|
|
PMC22 |
|
RELATIVE WEIGHTS ASSIGNED TO PHARMACY PROCEDURES:
OPPS METHODS DESIGN AND CONCEPTS
Baker JJ
The Resource Group, Dallas, TX, USA |
|
|
PMC23 |
|
ECONOMIC EVALUATION OF MEDICAL DEVICES IN FRANCE: A
CHALLENGE FOR HEALTH ECONOMISTS
Späth HM1, Taboulet F2, Carrère MO1
1GRESAC, Centre Léon Bérard, Lyon, France; 2
University Toulouse 3, Toulouse, France |
|
|
PMC24 |
|
USE OF PHARMACOECONOMICS/HEALTH ECONOMIC TOOL
(PE/HE) IN LOCAL HEALTH CARE DECISION MAKING (DM)
Soto H1, Guzman S2, Reynoso N2,
Cortes L3
1Universidad Autonoma del Estado de Mexico, Toluca, Mexico;
2 Universidad Autonoma del Estado de Mexico, Estado de México,
Mexico; 3 Instituto Mexicano de Seguro Social, Guadalajara,
Mexico |
|
|
PMC25 |
|
ANALYSIS OF QUALITY OF LIFE DATA FROM DIFFERENT
UTILITY INSTRUMENTS – AN EXAMPLE USING IMPUTATION
Fitzgerald P, Tilden D, Aristides M
M-TAG, A division of IMS Health Economics and Outcomes Research, London,
United Kingdom |
|
|
PMC26 |
|
DEVELOPMENT AND VALIDATION OF A DUTCH VERSION OF THE
LONDON HANDICAP SCALE
Groothuis-Oudshoorn CG1, Chorus AM2, Detmar
SE2, Hosli EJ2, Beekum W2, Verrips G2
1Roessingh Research and Development, Enschede, Netherlands;
2 TNO Quality of Life, Leiden, Netherlands |
|
|
PMC27 |
|
THE DEVELOPMENT OF A TREATMENT SATISFACTION
QUESTIONNAIRE FOR IRON OVERLOAD (IO) PATIENTS ON CHELATION THERAPY (CT)
Abetz L1, Baladi JF2, Jones P2,
Rofail D1
1Mapi Values, Macclesfield, Cheshire, United Kingdom; 2
Novartis Pharmaceutical Corporation, East Hanover, PA, USA |
|
|
PMC28 |
|
ITEM RESPONSE BIAS IN INSTRUMENTAL ACTIVITY DAILY
LIVING SCALE IN ASIAN OLDER ADULTS
Niti M1, Ng TP1, Chiam PC2, Kua
EH1
1National University of Singapore, Singapore, Singapore,
Singapore; 2 Institute of Mental Health, Singapore, Singapore,
Singapore |
|
|
|
|
.........................TOP |
|
|
ALLERGY |
|
|
PAL1 |
|
DETERMINING THE MINIMAL CLINICALLY IMPORTANT
DIFFERENCE FOR THE ESPRINT-15 QUESTIONNAIRE FOR PATIENTS WITH ALLERGIC
RINHITIS
Baro E1, On Behalf of Esprint Study Investigators .2
13D Health Research, Barcelona, Spain; 2 Esprint
Study Investigators Group, Barcelona, Spain |
|
|
PAL2 |
|
ATTRIBUTES FOR PREFERENCE OF NEW FAST DISSOLVING
TABLET (FDT) FORMULATION OF EBASTINE IN PATIENTS WITH ALLERGY
Roger A1, Fortea J2,
Artes M3, Montilla L3
1Centre Roger Barri d'Asmologia i Al.lèrgia, Barcelona,
Spain; 2 Laboratorios Almirall, Barcelona, Spain; 3
Adelphi Targis, S.L, Barcelona, Spain |
|
|
PAL3 |
|
DEVELOPMENT, PILOT TESTING, SCORING AND VALIDATION
OF A MANAGEMENT TOOL FOR PATIENTS UNDERGOING SPECIFIC IMMUNO-THERAPY
Arnould B1, Benmedjahed K2, Fadel R3,
Bos C3, Fontaine JF4, Haddad T5,
Mathelier Fusade P5, Rufin P5, Saint Martin F6,
Zekri J7, Viala M2
1Mapi Values, Lyon, Rhone, France; 2 Mapi Values,
Lyon, France; 3 Stallergènes, Antony, France; 4
Private practice, Reims, France; 5 Private practice, Paris,
France; 6 Private practice, Villebon sur Yvette, France;
7 Private practice, Toulouse, France |
|
|
.........................TOP |
|
|
ARTHRITIS |
|
|
PAR1 |
|
COSTS AND EFFECTS OF CELECOXIB IN THE TREATMENT OF
PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS IN THE NETHERLANDS
Al M1, Janssen M2, Monteban HC3
1Institute for Medical Technology Assessment, Rotterdam,
Netherlands; 2 Rijnstate Hospital, Arnhem, Netherlands; 3
Pfizer bv, Capelle a/d IJssel, Netherlands |
|
|
PAR2 |
|
METAL ON METAL (MOM) HIP RESURFACING (BIRMINGHAM HIP
RESURFACING (BHR)) IN YOUNG PATIENTS WITH SEVERE HIP DAMAGE – A COST
UTILITY ANALYSIS
Richardson JB1, Band T2, Barnes DC1,
Buckland AG3,
Posnett J4
1RJAH Orthopaedic & District Hospital NHS Trust, Oswestry,
Shropshire, United Kingdom; 2 Smith & Nephew Orthopaedics Ltd,
Birmingham, United Kingdom; 3 Abacus International, Bicester,
Oxfordshire, United Kingdom; 4 Smith & Nephew Wound
Management, Hull, United Kingdom |
|
|
PAR3 |
|
PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS
SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT MODERATE TO SEVERE
OSTEOARTHRITIS (OA) PAIN OF THE HIP/KNEE
Marshall DA1, Strauss ME2, Pericak D1,
Buitendyk M1, Codding C3, Torrance G1
1Innovus Research Inc, Burlington, ON, Canada; 2
Purdue Pharma L.P, Stamford, CT, USA; 3 Oklahoma Sports,
Oklahoma City, OK, USA |
|
|
PAR4 |
|
OSTEOARTHRITIS: CHONDROITIN SULFATE LONG TERM
UTILIZATION IS COST-SAVING.
Taieb C1, Huichard C2, Labed D2,
Myon E3
1Pierre Fabre, Boulogne-Billancourt, France; 2 IMS
Health, Puteaux, France; 3 Pierre Fabre SA, Boulogne
Billancourt, France |
|
|
PAR5 |
|
OSTEOARTHRITIS: CHONDROITIN SULFATE LONG TERM
UTILIZATION REDUCES CONSUMPTION OF COXIBS, NSAIDS & ANALGESICS.
Taieb C1, Labed D2, Huichard C2,
Myon E1
1Pierre Fabre, Boulogne-Billancourt, France; 2 IMS
Health, Puteaux, France |
|
|
PAR6 |
|
GASTROINTESTINAL (GI) EVENTS, MEDICATION USE AND
HEALTHCARE COSTS FOR NEW USERS OF CYCLOOXYGENASE (COX)-2 INHIBITORS AND
NONSELECTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
Gilmore A1, Seelig M2, Lalla A1,
Legorreta A3
1Health Benchmarks, Inc, Woodland Hills, CA, USA; 2
David Geffen School of Medicine at UCLA, Woodland Hills, CA, USA; 3
UCLA School of Public Health, Woodland Hills, CA, USA |
|
|
PAR7 |
|
WITHDRAWN |
|
|
PAR8 |
|
COST COMPARISON OF THE COMBINATION TRAMADOL PLUS
PARACETAMOL VERSUS NSAIDS PLUS PROTON PUMP INHIBITORS IN THE TREATMENT OF
OSTEOARTHRITIS IN THE NETHERLANDS
Liedgens H1, Nuijten MJ2, Poulsen Nautrup B1
1Gruenenthal GmbH, Aachen, Germany; 2 Erasmus
University, Rotterdam, Netherlands |
|
|
PAR9 |
|
A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3
UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF
THE KNEE
Marshall D1, Grootendorst P2, Pericak D1,
Bellamy N3, Feeny D4, Gooch K5, Frank C6,
Torrance G1
1Innovus Research Inc, Burlington, ON, Canada; 2
University of Toronto, Toronto, ON, Canada; 3 University of
Queensland, Brisbane, Queensland, Australia; 4 University of
Alberta and Institute of Health Economics, Edmonton, AB, Canada; 5
Institute of Health Economics, Calgary, AB, Canada; 6
University of Calgary, Calgary, AB, Canada |
|
|
PAR10 |
|
ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE
INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH CORE
SETS FOR OSTEOARTHRITIS FROM THE PERSPECTIVE OF PATIENTS WITH KNEE
OSTEOARTHRITIS IN SINGAPORE
Xie F1, Thumboo J2, Fong KY2, Lo
NN2, Yeo SJ2, Yang KY2, Li SC1
1National University of Singapore, Singapore, Singapore,
Singapore; 2 Singapore General Hospital, Singapore, Singapore,
Singapore |
|
|
PAR11 |
|
VALIDITY STUDIES AND SATISFACTION THRESHOLD OF THE
ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)
Ruíz M1, Rejas J2, Campillo M3,
Monfort J3, Fernández S2, Soto J2, Pardo
A1
1College of Psychology, Universidad Autónoma de Madrid, Ciudad
Universitaria de Cantoblanco, Madrid, Spain; 2 Pfizer Spain,
Alcobendas, Madrid, Spain; 3 Hospital del Mar, Barcelona,
Barcelona, Spain |
|
|
PAR12 |
|
IMPROVEMENT IN HEALTH UTILITY IN PATIENTS WITH
PSORIATIC ARTHRITIS TREATED WITH ADALIMUMAB (HUMIRA®)
Anis AH1, Guh D2, Melilli LE3
1University of British Columbia, Vancouver, BC, Canada; 2
Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada;
3 Abbott Laboratories, Abbott Park, IL, USA |
|
|
PAR13 |
|
THE DIRECT MEDICAL COST OF RHEUMATOID ARTHRITIS IN
HONG KONG
Lee VWY, Li EK, Tam LS, Chan CW, Chan LH, Ng TS, Lee KK
The Chinese University of Hong Kong, Shatin, Hong Kong, China |
|
|
PAR14 |
|
EVALUATION OF ACCESS TO HIGH-COST MEDICINES IN
AUSTRALIA USING NATIONAL CLAIMS DATA
Lu CY, Williams K, Day R
University of New South Wales, Sydney, New South Wales, Australia |
|
|
PAR15 |
|
TARGETED ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA:
EARLY ANALYSIS FROM A QUALITATIVE STUDY
Lu CY, Ritchie J, Williams K, Day R
University of New South Wales, Sydney, New South Wales, Australia |
|
|
PAR16 |
|
POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE
COST-EFFECTIVENESS: RESULTS FROM AN ANALYSIS OF ETANERCEPT USE IN
RHEUMATOID ARTHRITIS
Farahani P, Goeree R, Gaebel K, Levine M
McMaster University, Hamilton, ON, Canada |
|
|
PAR17 |
|
BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID
ARTHRITIS IN HUNGARY
Péntek M1, Kobelt G2, Szekanecz Z3,
Poór G4, Czirják L5, Rojkovich B6, Genti
G1, Polgár A7, Kiss CG5, Lepp-Gazdag A8,
Brodszky V8, Májer I8, Gulácsi L8
1Flór Ferenc County Hospital, Kistarcsa, Hungary; 2
European Health Economics, Speracedes, France; 3 University of
Debrecen Medical and Health Sciences Center, Debrecen, Hungary; 4
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary;
5 Hungarian Brothers of St. John of God and University of
Pécs, Pécs, Hungary; 6 Polyclinic of the Hospitaller Brothers
of St. John of God, Budapest, Hungary; 7 National Medical
Center, Budapest, Hungary; 8 Corvinus University of Budapest,
Budapest, Hungary |
|
|
PAR18 |
|
PATIENT COMPLIANCE IN THE TREATMENT OF RHEUMATOID
ARTHRITIS WITH BIOLOGIC DMARDS AND PREDICTING FACTORS: A LITERATURE
REVIEW
Schmidt E1, Kielhorn A2
1Analytica International GmbH, Loerrach, Germany; 2
F. Hoffmann-La Roche Ltd, Basel, Switzerland |
|
|
PAR19 |
|
CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS
FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE
IN EARLY RHEUMATOID ARTHRITIS (RA)
Cifaldi M1, Sterz R2, Dietz B2,
Chmiel J1, Spencer-Green GT3
1Abbott Laboratories, Abbott Park, IL, USA; 2
Abbott GmbH and Co KG, Ludwigshafen, Germany; 3 Abbott
Laboratories, Parsippany, NJ, USA |
|
|
PAR20 |
|
EFFECTS OF LONG-TERM ADALIMUMAB THERAPY ON HEALTH
UTILITY AND FATIGUE IN PATIENTS WITH LONG-STANDING, SEVERE RHEUMATOID
ARTHRITIS (RA) - RESULTS FROM A 3-YEAR FOLLOW-UP STUDY
Mittendorf T1, Sterz R2, Von der
Schulenburg J1, Kupper H2, Cifaldi M3,
Dietz B2
1University of Hannover, Hannover, Germany; 2
Abbott GmbH and Co KG, Ludwigshafen, Germany; 3 Abbott
Laboratories, Abbott Park, IL, USA |
|
|
|
|
.........................TOP |
|
|
ASTHMA |
|
|
PAS1 |
|
WITHDRAWN |
|
|
PAS2 |
|
FLUTICASONE PROPIONATE/ SALMETEROL COMBINATION
IMPROVES HEALTH OUTCOMES AND QUALITY OF LIFE IN CHILDREN WITH POORLY
CONTROLLED ASTHMA IN IRELAND
Hill P1,
Hughes J2, Grant D3, Sawyer W3,
Reeves P3
1Blackpool Health Centre, Cork City, Cork, Ireland; 2
GlaxoSmithKline Ireland, Dublin, Ireland; 3 Fourth Hurdle
Consulting Ltd, London, United Kingdom |
|
|
PAS3 |
|
ASTHMA CONTROL IN SPAIN. DOES TREATMENT PROFILE AND
SEASON MATTER?
Fueyo A1, Ruiz-Cobos MA2, Ancochea J2,
Badia X3
1Glaxosmithkline, Madrid, Spain; 2 Hospital La
Princesa, Madrid, Spain; 3 Health Outcomes Research Europe,
Barcelona, Spain |
|
|
PAS4 |
|
THE COST OF ASTHMA EXACERBATIONS OF DIFFERENT
SEVERITY LEVELS
Dewilde S1, Rapatz G2,
Turk F2
1The MEDTAP Institute at UBC, Brussels, Belgium; 2
Novartis Pharma AG, Basel, Switzerland |
|
|
PAS5 |
|
IMPACT OF MONTELUKAST THERAPY ON ASTHMA-RELATED
HEALTHCARE RESOURCES USE IN MILD TO MODERATE ASTHMATIC PATIENTS WITH
SEASONAL ALLERGIC RHINITIS IN SPAIN
Pinto Blázquez JA1, Blasco Redondo R2,
Sazonov Kocevar V3, Badia X4, Guilera M4,
Caloto MT5, Nocea G5
1Hospital Marqués de Valdecilla, Santander, Spain; 2
Centro de Medicina Deportiva, Junta de Castilla y León, Valladolid,
Spain; 3 Merck & Co, Whitehouse Station, NJ, USA; 4
Health Outcomes Research Europe, Barcelona, Spain; 5 Merck,
Sharp & Dohme, Madrid, Spain |
|
|
PAS6 |
|
CLINICAL OUTCOME OF CHRONIC ASTHMA
Reissell E1, Haukka J1, Minkkinen S1,
Laitinen T1, Salonoja M1, Pirskanen A1,
Palmu P1, Rehn M1, Honkanen H1, Lahtinen
T1, Lindqvist A2, Kunnas T1
1Geneos Ltd, Helsinki, Finland; 2 Helsinki
University Hospital, Helsinki, Finland |
|
|
PAS7 |
|
THE HUMAN IMPACT OF SEVERE PERSISTENT ALLERGIC
ASTHMA: RESULTS FROM A MULTINATIONAL STUDY
Turk F
Novartis Pharma AG, Basel, Switzerland |
|
|
PAS8 |
|
ASTHMA RELATED QUALITY OF LIFE IS CORRELATED WITH
ASTHMA CONTROL AMONG RESPIRE STUDY PARTICIPANTS
Moisan J1, Jobin MS1, Dorval E2,
Guénette L1, Bolduc Y3, Turcotte M4,
Grégoire JP1
1Université Laval, Québec, QC, Canada; 2 Merck
Frosst Canada, Kirkland, QC, Canada; 3 Clinique médicale
d'Alma, Alma, QC, Canada; 4 Centre de santé et de services
sociaux du Piekouagami, Alma, QC, Canada |
|
|
PAS9 |
|
THE SPANISH VERSION OF THE MINI-ASTHMA QUALITY OF
LIFE QUESTIONNAIRE: EXAMINATION OF RESPONSIVENESS TO CHANGE
Caloto MT1, Prieto L2, Hinojosa M3,
Colás C4, Feo F5, Nocea G1
1Merck, Sharp & Dohme, Madrid, Spain; 2 Hospital
Universitario Dr Peset, Valencia, Spain; 3 Hospital Ramón y
Cajal, Madrid, Spain; 4 Hospita Clínico, Zaragoza, Spain;
5 Hospital Alarcos, Ciudad Real, Spain |
|
|
|
|
.........................TOP |
|
|
CANCER |
|
|
PCN1 |
|
ECONOMIC IMPACT OF ADOPTING PEMETREXED PLUS
CISPLATIN FOR MALIGNANT PLEURAL MESOTHELIOMA INTO SCOTTISH CLINICAL
PRACTICE
Chetty M1, Cordony A2, Davey P2,
Karampela K1, Le Reun C2, Watt M1
1Eli Lilly and Company, Basingstoke, United Kingdom; 2
M-TAG Pty Ltd, Chatswood, Australia |
|
|
PCN2 |
|
LEAD TIME IN THE EVALUATION OF HISTORICAL SURVIVAL
IMPROVEMENTS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Martins R1,
Ramsey SD2, Blough D3
1Seattle Cancer Care Alliance, Seattle, WA, USA; 2
Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3
University of Washington, Seattle, WA, USA |
|
|
PCN3 |
|
POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT
(EMEND) IN HIGHLY EMETOGENIC CISPLATINE-BASED CHEMOTHERAPY
Le Lay K1, Francesconi C1, Briand Y2,
Souchet T2,
Launois R3
1REES France, Paris, France; 2 Merck Sharp & Dohme
– Chibret, Paris, France; 3 REES France, Paris, Paris, France |
|
|
PCN4 |
|
COST OF CARE AND ECONOMIC IMPACT OF CETUXIMAB IN THE
TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
Rubio M1, Badia X1, Mercadé J2
1Health Outcomes Research Europe, Barcelona, Spain; 2
Merck Farma y Química, Mollet del Vallés, Barcelona, Spain |
|
|
PCN5 |
|
THE COST OF SECOND-LINE TREATMENT OF OVARIAN CANCER
IN POLISH SETTINGS
Macioch T1, Niewada M2, Golicki D1,
Kamiñski B3, Jakubczyk M4
1Medical University of Warsaw, Warsaw, Woj. Mazowieckie,
Poland; 2 Medical University of Warsaw, Warsaw, Poland; 3
Warsaw School of Economics, Warszawa, mazowieckie, Poland; 4
Warsaw School of Economics, Warsaw, Poland |
|
|
PCN6 |
|
POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT
(EMEND) IN MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)
Francesconi C1, Le Lay K1, Souchet T2,
Briand Y2,
Launois R1
1REES France, Paris, France; 2 Merck Sharp & Dohme
– Chibret, Paris, France |
|
|
PCN7 |
|
COST ANALYSIS OF 3-YEARS FOLLOW-UP OF A TRASTUZUMAB
TREATED COHORT
Le Lay K1, Devaux M1, Lotz JP2,
Tsé C2, Brault D2, Launois R1
1REES France, Paris, France; 2 Service d’Oncologie
Médicale – Hôpital Tenon, Paris, France |
|
|
PCN8 |
|
INITIATION OF TRANSDERMAL OPIOID THERAPY IN CANCER
PATIENTS WITH MODERATE OR SEVERE MALIGNANT PAIN – TREATMENT PATTERNS AND
COSTS IN A GERMAN UNIVERSITY HOSPITAL
Paessens B1, Ehlken B2, Lippert B2,
Berger K2, Steffen A1, Bernard R1,
Ihbe-Heffinger A1
1Klinikum rechts der Isar, Technische Universität München,
Munich, Germany; 2 MERG, Medical Economics Research Group,
Munich, Germany |
|
|
PCN9 |
|
COST COMPARISON ANALYSIS OF INTRAVENOUS VERSUS
COMBINED INTRAVENOUS-ORAL CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG
CANCER
Skowron A, Brandys J
Jagiellonian University, Cracow, Malopolska, Poland |
|
|
PCN10 |
|
THE COST-EFFECTIVENESS OF POST-OPERATIVE
RADIOTHERAPY AFTER BREAST CONSERVATION SURGERY IN STAGEI-II BREAST CANCER
IN SWEDEN
Persson U1, Borg S1, Ferras-Nunes J2,
Franzen S3, Genell A4, Malmström P5,
Wallgren A2, Östlund A6, Alvegård T5
1IHE, The Swedish Institute for Health Economics, Lund,
Sweden; 2 Gothenburg University, Gothenburg, Sweden; 3
West Health Care Region, Gothenburg, Sweden; 4 Onkologiskt
centrum, Sahlgrenska Universitetssjukhuset, Gothenburg, Sweden; 5
Lund University Hospital, Lund, Sweden; 6 West Health Care
Region, Gothenburg, Borås, Sweden |
|
|
PCN11 |
|
ECONOMIC EVALUATION OF BORTEZOMIB IN THE TREATMENT
OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS IN CANADA
Yoong K1, Bagust A2, Haycox A2,
Mujica-Mota R2, Dhawan R3
1Janssen-Ortho Inc, Toronto, Ontario, Canada; 2
University of Liverpool, Liverpool, United Kingdom; 3 Johnson
& Johnson Pharmaceutical Services LLC, Raritan, NJ, USA |
|
|
PCN12 |
|
IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR
EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL,
DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL,
DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE
Miadi-Fargier H1, Le Pen C1, Woronoff-Lemsi
MC2, Guastalla JP3, Pivot X2, Roché H4,
Pinguet F5, Favier B3, Gligorov J6,
Debrix I6, Spielmann M7, Antoine EC8,
Cadilhac M9, De Pouvourville GA10
1AREMIS Consultants, Neuilly-sur-Seine, France; 2
CHU de Besançon – Hôpital Jean Minjoz, Besançon, France; 3
Centre Léon Bérard, Lyon, France; 4 Institut Claudius Regaud,
Toulouse, France; 5 CRLC Val d’Aurelle, Montpellier, France;
6 Hôpital Tenon, Paris, France; 7 Institut Gustave
Roussy, Villejuif, France; 8 Clinique Hartman,
Neuilly-sur-Seine, France; 9 Sanofi-Aventis, Paris, France;
10 INSERM, Le Kremlin Bicêtre, France |
|
|
PCN13 |
|
COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR
METASTATIC COLORECTAL CANCER (CALGB 9481)
Weeks JC1,
Romanus D1, Herndon II JE2, Schrag D3,
Mayer RJ1, Kemeny N3
1Dana-Farber Cancer Institute, Boston, MA, USA; 2
CALGB Statistical Center, Durham, NC, USA; 3 Memorial
Sloan-Kettering Cancer Center, New York, NY, USA |
|
|
PCN14 |
|
COST-EFFECTIVENESS ANALYSIS OF ARANESP® (DARBEPOETIN
ALFA) ADMINISTERED ONCE EVERY THREE WEEKS COMPARED TO ONCE EVERY WEEK
Demarteau N, Annemans L
IMS Health, Brussels, Belgium |
|
|
PCN15 |
|
PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS
TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN
RECEPTOR-POSITIVE BREAST CANCER
Gil JM1, Lluch A2,
González P3, Del Castillo A3, Canorea F3,
Rubio-Terrés C4
1Institut Catalá d’Oncologia, L’Hospitalet de Llobregat,
Barcelona, Spain; 2 Hospital Clínico Universitario de
Valencia, Valencia, Spain; 3 Pfizer, Alcobendas, Madrid,
Spain; 4 HERO Consulting, Madrid, Spain |
|
|
PCN16 |
|
ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY APPEARS
DOMINANT VS. CHEMOTHERAPY ALONE IN ADVANCED STAGE NHL – INTERIM RESULTS
FROM A RANDOMIZED CLINICAL TRIAL (RCT)
Hieke K1, Herold M2
1Neos Health, Binningen, Switzerland; 2 Helios
Kliniken, Erfurt, Germany |
|
|
PCN17 |
|
THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION
WITH IRINOTECAN FOR THE TREATMENT OF PATIENTS WITH EGFR-EXPRESSING
METASTATIC COLORECTAL CANCER AFTER FAILURE OF IRINOTECAN-INCLUDING
CYTOTOXIC THERAPY IN SCOTLAND
Tilden D1, Thurley D2, White J2,
Aristides M1
1M-TAG, A division of IMS Health Economics and Outcomes
Research, London, United Kingdom; 2 Merck Pharmaceuticals UK,
London, United Kingdom |
|
|
PCN18 |
|
LETROZOLE (FEMARA) IS A COST-EFFECTIVE TREATMENT IN
THE EXTENDED ADJUVANT SETTING IN WOMEN WITH EARLY BREAST CANCER: AN
APPLICATION TO CANADA
El Ouagari K, Talbot W
Novartis Pharma, Dorval, QC, Canada |
|
|
PCN19 |
|
AUSTRALIAN COST-EFFECTIVENESS ANALYSIS OF
ANASTROZOLE VS TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER
BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL
Benedict A1, Theodoratou D1, Maclean A2,
Norris S3, Campbell S3, Mernagh P3
1MedTap Institute at UBC, London, United Kingdom; 2
AstraZeneca Pty Ltd, North Ryde, NSW, Australia; 3 Health
Technology Analysts Pty Ltd, Balmain, NSW, Australia |
|
|
PCN20 |
|
ORAL AND INTRAVENOUS CHEMOTHERAPY FOR FIRST LINE
TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK NHS SYSTEM
Le Lay K1, Myon E2, Hill S3,
Riou França L1, Scott D4, Sidhu M4,
Dunlop D5, Launois R1
1REES France, Paris, France; 2 Pierre Fabre,
Boulogne-Billancourt, France; 3 Pierre Fabre Ltd, Winchester,
Hampshire, England; 4 Fourth Hurdle Consulting Ltd, London,
United Kingdom; 5 Beatson Oncology Centre, Glasgow, United
Kingdom |
|
|
PCN21 |
|
TREATMENT COST OF COLORECTAL CANCER CHEMOTHERAPIES
IN GERMANY
Hieke K1, Grothey A2
1Neos Health, Binningen, Switzerland; 2 Mayo Clinic
College of Medicine, Rochester, MN, USA |
|
|
PCN22 |
|
COSTS OF COMMON TREATMENT OPTIONS FOR INDOLENT
FOLLICULAR NON-HODGKIN’S LYMPHOMA
Van Agthoven M1, Hagenbeek A2, Uyl-de Groot
CA1
1Erasmus MC – University Medical Center Rotterdam, Rotterdam,
ZH, Netherlands; 2 University Medical Center Utrecht, Utrecht,
UT, Netherlands |
|
|
PCN23 |
|
ECONOMIC ASPECTS AND DRIVERS OF FEBRILE NEUTROPENIA
IN CANCER – A MULTICENTRE RETROSPECTIVE ANALYSIS IN BELGIUM
Moeremans K, Caekelbergh K, Spaepen E, Annemans L
IMS Health, Brussels, Belgium |
|
|
PCN24 |
|
ESTIMATING THE COST OF INFORMAL CAREGIVING IN LUNG
CANCER PATIENTS. THE HABIT STUDY
Mangone M1, Busca R2, Ciobanu A1,
Negrini C2
1AstraZeneca S.p.a, Basiglio, Milan, Italy; 2 Pbe
Consulting, Milan, Milan, Italy |
|
|
PCN25 |
|
INFLUENCE OF THE PORTION OF MEDICAL EXPENSE PAID
INDIVIDUALLY ON PHYSICIANS’ ATTITUDE TOWARDS CANCER TREATEMENT IN JAPAN
Saito S1, Shimozuma K2
1Kochi Women’s University, Kochi, Japan; 2
University of Marketing and Distribution Sciences, Kobe, Japan |
|
|
PCN26 |
|
CUTANEOUS CANCER TREATMENT AND COSTS IN GERMANY
Nijhuis T1, Radny P2
1Quintiles Consulting, Hoofddorp, Netherlands; 2
University of Freiburg, Freiburg, Germany |
|
|
PCN27 |
|
ECONOMIC ANALYSIS OF BISPHOSPHONATES FROM THE PAYERS
PERSPECTIVE IN BRAZIL
Calabró AA
Novartis Biociências, São Paulo, São Paulo, Brazil |
|
|
PCN28 |
|
DOCUMENTATION OF PHARMACY COST IN THE PREPARATION OF
CHEMOTHERAPY INFUSIONS IN ACADEMIC AND COMMUNITY-BASED ONCOLOGY PRACTICES
Brixner D, Nickman N, Oderda GM
University of Utah College of Pharmacy, Salt Lake City, UT, USA |
|
|
PCN29 |
|
PER-PATIENT COST OF HOSPITAL CARE FOR ADVANCED
BREAST CANCER IN THE UK BASED ON A PATIENT-LEVEL RESOURCE UTILISATION
DATASET
Wolowacz S1, Roskell N1, Christie A2,
Kerr G3, Cameron D3
1RTI Health Solutions, Manchester, United Kingdom; 2
Sanofi-Aventis, Guildford, Surrey, United Kingdom; 3 Western
General Hospital, Edinburgh, Scotland, United Kingdom |
|
|
PCN30 |
|
COMPARATIVE ANALYSIS OF DRUG COST OF BREAST,
CERVICAL AND COLORECTAL CANCER IN HUNGARY
Boncz I1, Sebestyen A2,
David T1
1National Health Insurance Fund Administration (OEP),
Budapest, Hungary; 2 National Health Insurance Fund
Administration (OEP), Pécs, Hungary |
|
|
PCN31 |
|
COST EFFECTIVENESS MODEL OF IV BISPHOSPHONATES IN
THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE
METASTASES: A GERMAN INPATIENT PERSPECTIVE
Botteman M1, Hay J2, Stephens JM1,
Barghout V3, Quednau K4
1Pharmerit North America LLC, Bethesda, MD, USA; 2
University of Southern California, Los Angeles, CA, USA; 3
Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA; 4
Novartis Pharma GmbH, Nuernberg, Germany |
|
|
PCN32 |
|
COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS
TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE
POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK
Karnon J1, Delea TE2, Papo NL3,
Barghout V4, Thomas SK5, Johnston SR6
1University of Sheffield, Sheffield, United Kingdom; 2
Policy Analysis Inc, Brookline, MA, USA; 3 Novartis
Pharmaceuticals UK Ltd, Camberley, United Kingdom; 4 Novartis
Pharmaceuticals Corporation, Florham Park, NJ, USA; 5 Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA; 6 Royal
Marsden Hospital, London, United Kingdom |
|
|
PCN33 |
|
COST-UTILITY ANALYSIS OF CHEMOTHERAPY IN ADVANCED OR
RECURRENT GASTRIC CANCER: ORAL FLUOROPYRIMIDINE TS-1 VERSUS CONVENTIONAL
INTRAVENOUS CHEMOTHERAPY
Sakamaki H1, Ikeda S1, Yajima S1,
Ikegami N1, Tanaka K2, Murayama J2
1Keio University, Shinjuku-ku, Tokyo, Japan; 2
Showa University Hospital, Shinagawa-ku, Tokyo, Japan |
|
|
PCN34 |
|
COST-EFFECTIVENESS OF ANASTROZOLE OVER TAMOXIFEN IN
POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A UK NATIONAL HEALTH
SERVICE PERSPECTIVE: THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC
TRIAL
Brown R1, Benedict A1, Mansel R2
1MedTap Institute at UBC, London, United Kingdom; 2
University of Wales College of Medicine, Cardiff, United Kingdom |
|
|
PCN35 |
|
A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS
EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH
ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)
Pangali M1,
Christodoulopoulou A1, Ardavanis A2,
Barbounis V2, Galani E3, Skarlos D3
1AstraZeneca SA, Athens, Greece; 2 Saint Savvas
Hospital, Athens, Greece; 3 Henry Dunan Hospital, Athens,
Greece |
|
|
PCN36 |
|
A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY
REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCER AFTER ANTHRACYCLINE
FAILURE
Le Lay K1, Riou França L1, Avoinet S2,
Chemali N2, Launois R1
1REES France, Paris, France; 2 Lilly, Suresnes
Cedex, France |
|
|
PCN37 |
|
IMPACT OF HEALTH CARE REFORMS AND CHANGING PAYMENT
MECHANISMS ON HEALTH ECONOMIC EVALUATIONS IN GERMANY
Hieke K1, Grothey A2
1Neos Health, Binningen, Switzerland; 2 Mayo Clinic
College of Medicine, Rochester, MN, USA |
|
|
PCN38 |
|
ASSESSING THE IMPACT ON STAFF RESOURCE AND PATIENT
WAITING TIME OF A SWITCH FROM IV TO ORAL CHEMOTHERAPY: TIME AND MOTION
MODEL FOR HTAS
Taylor H1, Burcombe R1,
Hill S2, Cadwallader S2, James R1
1Kent Oncology Centre, Maidstone, United Kingdom; 2
Pierre Fabre Ltd, Winchester, Hampshire, United Kingdom |
|
|
PCN39 |
|
APPLICATION OF AN ALGORITHM FOR DEFINING
RETROSPECTIVE COHORTS OF COLORECTAL CANCER (CRC) PATIENTS TREATED WITH
DIFFERENT FIRST-LINE CHEMOTHERAPY REGIMENS +/- BEVACIZUMAB TO
ADMINISTRATIVE CLAIMS DATA
Cisternas MG1, Mrad R2, Noe LL1,
Miller DP1, Guyan C1
1Ovation Research Group, Highland Park, IL, USA; 2
F. Hoffmann-La Roche Ltd, Basel, Switzerland |
|
|
PCN40 |
|
DEVELOPMENT OF AN ALGORITHM FOR THE IDENTIFICATION
AND CLASSIFICATION OF COLORECTAL CANCER (CRC) PATIENTS ACCORDING TO
FIRST-LINE CHEMOTHERAPY +/- BEVACIZUMAB, AND INITIATION OF SECOND-LINE
THERAPY USING ADMINISTRATIVE CLAIMS RECORDS
Cisternas MG1, Mrad R2, Noe LL1,
Miller DP1, Guyan C1
1Ovation Research Group, Highland Park, IL, USA; 2
F. Hoffmann-La Roche Ltd, Basel, Switzerland |
|
|
PCN42 |
|
MODELLING THE EFFECT OF A NOVEL THERAPEUTIC AGENT ON
THE EVOLUTION OF UTILITY IN REFRACTORY MULTIPLE MYELOMA PATIENTS
Mujica-Mota R1, Bagust A1, Haycox AR1,
Dhawan R2
1University of Liverpool Management School, Liverpool, UK,
United Kingdom; 2 Johnson & Johnson Pharmaceutical Services
LLC, Raritan, NJ, USA |
|
|
PCN43 |
|
CRITICAL APPRAISAL OF SCIENTIFIC POSTERS COMPARING
ANEMIA TREATMENTS IN CANCER PATIENTS: APPLYING ISPOR TASK FORCE
GUIDELINES ON METHODOLOGICAL QUALITY OF RETROSPECTIVE STUDIES
Demarteau N, Moeremans K, Annemans L
IMS Health, Brussels, Belgium |
|
|
PCN44 |
|
HEALTH RELATED QUALITY OF LIFE EVALUATIONS IN
PROSTATE CANCER: WHO’S BEING STUDIED?
Ramsey SD1, Zeliadt S1, Hall IJ2,
Ekwueme DU2
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
2 Centers for Disease Control and Prevention, Atlanta, GA, USA |
|
|
PCN45 |
|
MULTILINGUAL VALIDATION OF THE FACT-LEUKEMIA IN 7
LANGUAGES
Eremenco SL, Arnold BJ, Cella D
Evanston Northwestern Healthcare, Evanston, IL, USA |
|
|
PCN46 |
|
WHAT ARE THE PSYCHOSOCIAL CONSEQUENCES OF AN
ABNORMAL SCREENING-MAMMOGRAPHY?
Brodersen J, Thorsen H
University of Copenhagen, Copenhagen, Denmark |
|
|
PCN47 |
|
VALIDATION OF THE SPANISH VERSION OF THE UCLA
PROSTATE CANCER INDEX: RELIABILITY AND VALIDITY OF A HEALTH-RELATED
QUALITY OF LIFE MEASURE.
Ibarz R1, Cavada E2, Casado A1,
Casimiro C2, and the CAVIPROS Study Group .3
13D Health Research, Barcelona, Spain; 2 Abbott
Laboratories S.A, Madrid, Spain; 3 CAVIPROS Study Group,
Barcelona, Spain |
|
|
PCN48 |
|
WITHDRAWN |
|
|
PCN49 |
|
HEALTH STATE DESCRIPTIONS FOR METASTATIC BREAST
CANCER: A QUALITATIVE STUDY
Narewska J1, Nafees B1,
Lloyd A1, Watkins JR2
1MEDTAP Institute at UBC, London, United Kingdom; 2
Eli Lilly and Company Limited, UK, Basingstoke, Hampshire, United Kingdom |
|
|
PCN50 |
|
A PILOT STUDY ASSESSING THE QUALITY OF LIFE IMPACT
OF ADVERSE EVENTS EXPERIENCED BY ADVANCED NON-SMALL-CELL LUNG CANCER
PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY
Tilden D1, Hill G1, Watt M2,
Bhalla S3
1M-TAG, A division of IMS Health Economics and Outcomes
Research, London, United Kingdom; 2 Eli Lilly and Company,
Basingstoke, United Kingdom; 3 Eli Lilly and Company, Surrey,
United Kingdom |
|
|
PCN51 |
|
DEVELOPMENT OF A NEW SCALE TO ASSESS PATIENT
PERCEPTIONS OF CANCER-RELATED FATIGUE: THE PERFORM PROJECT
Baro E1, Gasquet JA2, Herdman M3,
Sánchez J2, Colillas N3
13D Health Research, Barcelona, Spain; 2 Amgen,
Barcelona, Spain; 3 3D Health Research, Barcelona, Barcelona,
Spain |
|
|
PCN52 |
|
ASSESSING QOL IN PATIENTS WITH METASTATIC COLORECTAL
CANCER (MCRC) TREATED WITH CHEMOTHERAPY
Miller KL1, Johnson LL1, Colwell HH1,
Bhattacharyya SK2, Deeter RG2,
Mathias SD1
1Ovation Research Group, San Francisco, CA, USA; 2
Amgen, Inc, Thousand Oaks, CA, USA |
|
|
PCN53 |
|
MONITORING AND SECURING QUALITY IN ONCOLOGICAL CARE
– THE 2004 LONGITUDINAL PASQOC® RESULTS
Behrens M1, Kleeberg UR2, Heiden I3
1GlaxoSmithKline GmbH & Co. KG, Munich, Germany; 2
Hamburg Cancer Society, Hamburg, Germany; 3 Picker Institute,
Hamburg, Germany |
|
|
|
|
.........................TOP |
|
|
FIBROMYALGIA |
|
|
PFM1 |
|
FIBROMYALGIA SYNDROME: A PORTUGUESE EPIDEMIOLOGICAL
SURVEY
Branco J1, Saraiva F2, Taieb C3,
Myon E3
1Hospital Egas Moniz, Lisboa, Portugal; 2 Hospital
Santa Maria, Lisboa, Portugal; 3 Pierre Fabre,
Boulogne-Billancourt, France |
|
|
PFM2 |
|
FIBROMYALGIA SYNDROME: AN ITALIAN EPIDEMIOLOGICAL
SURVEY
Zoppi M1, Branco J2, Taieb C3,
Matucci Cerinic M1, Myon E3
1Univ Florence, Firenze, Italy; 2 Hospital Egas
Moniz, Lisboa, Portugal; 3 Pierre Fabre, Boulogne-Billancourt,
France |
|
|
PFM3 |
|
CROSS-SURVEY OF FRENCH AND PORTUGUESE GENERAL
PRACTITIONERS GLOBAL MANAGEMENT OF FIBROMYALGIA
Blotman F1, Branco J2, Barros H3,
Thomas E1, Taieb C4, Myon E4
1Lapeyronie Hospital, Montpellier, France; 2
Hospital Egas Moniz, Lisboa, Portugal; 3 ON-DOR, Porto,
Portugal; 4 Pierre Fabre, Boulogne-Billancourt, France |
|
|
PFM4 |
|
DIAGNOSIS OF FIBROMYALGIA AND HEALTHCARE RESOURCE
USE IN PRIMARY CARE IN THE UNITED KINGDOM
Myon E1, Wessely S2, Annemans L3,
Spaepen E3, Taieb C1
1Pierre Fabre, Boulogne-Billancourt, France; 2 GKT
School of Medicine & Institute of Psychiatry, London, England; 3
IMS Health, Brussels, Belgium |
|
|
PFM5 |
|
CROSS-SURVEY OF FRENCH AND PORTUGUESE
RHEUMATOLOGISTS GLOBAL MANAGEMENT OF FIBROMYALGIA
Blotman F1, Branco J2, Barros H3,
Thomas E1, Taieb C4, Myon E4
1Lapeyronie Hospital, Montpellier, France; 2
Hospital Egas Moniz, Lisboa, Portugal; 3 ON-DOR, Porto,
Portugal; 4 Pierre Fabre, Boulogne-Billancourt, France |
|
|
PFM6 |
|
CROSS-SURVEY OF FRENCH AND PORTUGUESE GENERAL
PRACTITIONERS AWARENESS AND KNOWLEDGE OF FIBROMYALGIA
Blotman F1, Branco J2, Barros H3,
Thomas E1, Taieb C4, Myon E4
1Lapeyronie Hospital, Montpellier, France; 2
Hospital Egas Moniz, Lisboa, Portugal; 3 ON-DOR, Porto,
Portugal; 4 Pierre Fabre, Boulogne-Billancourt, France |
|
|
|
|
.........................TOP |
|
|
INFECTION |
|
|
PIN1 |
|
ASSESSING THE EXTERNAL VALIDITY OF DROTRECOGIN ALFA
(ACTIVATED) CLINICAL TRIALS IN AN OBSERVATIONAL STUDY USING PROPENSITY
SCORE MATCHING TO REDUCE RECRUITMENT BIAS
Riou França L1, Payet S1, Le Lay K1,
Vallet B2, Dhainaut JF3, Launois R1
1REES France, Paris, France; 2 Huriez Hospital,
University Hospital of Lille, Lille, France; 3 Paris V
University, Paris, France |
|
|
PIN2 |
|
ECONOMIC IMPLICATION OF HEPATITIS B VIRAL (HBV) LOAD
REDUCTION FOR ENTEVAVIR IN HEPATITIS B E ANTIGEN-POSITIVE CHRONIC
HEPATITIS B (CHB) PATIENTS
Yuan Y1, Iloeje U2, Cross A2,
Hay J3
1Bristol-Myers Squibb Company, Plainsboro, NJ, USA; 2
Bristol-Myers Squibb Company, Wallingford, CT, USA; 3
University of Southern California, Los Angeles, CA, USA |
|
|
PIN3 |
|
COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH
PEGINTERFERON ALFA 2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN
PATIENTS WITH CHRONIC C HEPATITIS (CHC) AND PERSISTENTLY NORMAL ALT
LEVELS (PNALT)
Rubio Terres C1,
Álvarez Sanz C2, Patel KK3
1HERO CONSULTING, Madrid, Madrid, Spain; 2 Roche
Farma S.A, Madrid, Madrid, Spain; 3 Hoffmann-La Roche, Nutley,
NJ, USA |
|
|
PIN4 |
|
COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE
ANTIMICROBIAL TREATMENTS FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Martin M1, Quilici S1, Garau J2,
File TM3, Kubin M4
1Innovus Research (UK) Ltd, High Wycombe, United Kingdom;
2 Hospital Mutua de Terassa, Barcelona, Spain; 3 Summa
Health System, Akron, OH, USA; 4 Bayer Healthcare AG,
Wuppertal, Germany |
|
|
PIN5 |
|
DYNAMIC MODELLING FOR ESTIMATING THE
COST-EFFECTIVENESS OF A CHLAMYDIA TRACHOMATIS SCREENING PROGRAM
De Vries R1, Postma MJ1, De Jong - van den
Berg LT1, Van Bergen J2
1University of Groningen, Groningen, Groningen, Netherlands;
2 Foundation for STI Control, Amsterdam, Noord Holland,
Netherlands |
|
|
PIN6 |
|
INFECTIONS CAUSED BY RESISTANT CANDIDA
SPECIES: COST-MINIMIZATION ANALISYS OF ANTIFUNGAL THERAPY IN BRAZIL
Guerra AL1, Monaco MF2, Follador W2
1Pfizer Laboratories Brazil, Sao Paulo, Brazil; 2
Pfizer Laboratories Brazil, Sao Paulo, Sao Paulo, Brazil |
|
|
PIN7 |
|
WITHDRAWN |
|
|
PIN8 |
|
INCREASED MANAGEMENT NEEDS AND CARE COSTS FOR
NURSING HOME RESIDENTS WITH CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA
O'Brien JA, Duran PA
Caro Research Institute, Concord, MA, USA |
|
|
PIN9 |
|
A COST UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A
(40KD) VERSUS PEGINTERFERON ALFA-2B (12KD) FOR THE TREATMENT OF CHRONIC
HEPATITIS C (CHC) IN THE UK
Latimer NR1, Lewis GJ2
1NERA Economic Consulting, London, London, United Kingdom;
2 Roche Products ltd, Welwyn Garden City, Hertfordshire,
United Kingdom |
|
|
PIN10 |
|
ANTIMICROBIAL TREATMENT OF ACUTE OTITIS MEDIA AND
ITS PHARMACOECONOMIC ANALYSIS IN SLOVAKIA
Banasova K1, Foltan V2, Hupkova H3,
Trupl J4
1Comenius University, Faculty of pharmacy, Bratislava, Slovak
Republic; 2 Comenius University, Faculty of pharmacy,
Bratislava, Slovakia, Slovak Republic; 3 H-LABOR, Bratislava,
Slovakia, Slovak Republic; 4 State Oncology Institute,
Bratislava, Slovakia, Slovak Republic |
|
|
PIN11 |
|
A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND
OUTCOME IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN
INNER-CITY HOSPITAL
Sakalis E1, Pan L2,
Wong SL3
1Bellevue Hospital Center, New York, NY, USA; 2
Ludwig Institute For Cancer Research, New York, NY, USA; 3
Pfizer Inc, Syosset, NY, USA |
|
|
PIN12 |
|
ASSESSEMENT OF THE EFFECT OF DROTRECOGIN ALPHA
(ACTIVATED) TREATMENT OF SEVERE SEPSIS ON BLEEDING EVENTS WITH COUNT
MODELS
Payet S1, Riou França L1, Le Lay K1,
Dhainaut JF2, Vallet B3, Launois R1
1REES France, Paris, France; 2 Paris V University,
Paris, France; 3 Hopital Claude Hurlez, Lille, France |
|
|
PIN13 |
|
SYSTEMATIC REVIEW ON THE SHARE OF ANTIBIOTIC THERAPY
COST IN RELATION OVERALL DIRECT TREAMENT COSTS OF MOST FREQUENT
NOSOCOMIAL AND COMMUNITY ACQUIRED INFECTIONS IN ADULTS
Dietrich ES1, Mielke A2, Saalbach KP3,
Frank U4
1National Association of Statutory Health Insurance
Physicians, Berlin, AK, Germany; 2 Federal Institute for drugs
and Medical Devices, Bonn, Germany; 3 Omnicare, Gütersloh,
Germany; 4 Institute of Environmental Medicine and Hospital
Epidemiology, Freiburg, Germany |
|
|
PIN14 |
|
IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED
BY CHRONIC HEPATITIS B INFECTION: ESTIMATES FROM INFECTED AMERICANS
Levy A1, Tafesse E2, Iloeje U3,
Mukherjee J2, Briggs A4
1Oxford Outcomes, Vancouver, British Columbia, Canada; 2
BMS, Wallingford, CT, USA; 3 Bristol-Myers Squibb Company,
Wallingford, CT, USA; 4 University of Glasgow, Glasgow, United
Kingdom |
|
|
PIN15 |
|
IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED
BY CHRONIC HEPATITIS B INFECTION: ESTIMATES FROM UNINFECTED AND INFECTED
PERSONS IN THE UK
Ossa DF1, Briggs A2, Tafesse E3,
Iloeje U4, Mukherjee J3, Lozano-Ortega G5,
Levy A6
1Oxford Outcomes, Oxford, United Kingdom; 2
University of Glasgow, Glasgow, United Kingdom; 3 BMS,
Wallingford, CT, USA; 4 Bristol-Myers Squibb Company,
Wallingford, CT, USA; 5 Oxford Outcomes, Vancouver, Britis
Columbia, Canada; 6 Oxford Outcomes, Vancouver, Bristis
Columbia, Canada |
|
|
PIN16 |
|
MEDICAL COSTS ASSOCIATED WITH NON-ADHERENCE TO
ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS
Merito M1, Ammassari A2, Trotta MP3,
Bonaccorsi A1, Antinori A3, D'Arminio Monforte A4
1Università di Pisa, Pisa, Italy; 2 Università
Cattolica del S. Cuore, Roma, Italy; 3 Istituto Nazionale per
le Malattie Infettive, Roma, Italy; 4 Università di Milano,
Milano, Italy |
|
|
PIN17 |
|
COST-EFFECTIVENESS ANALYSIS OF ENFUVIRTIDE ADDED TO
AN OPTIMISED THERAPY VS. AN OPTIMISED THERAPY ALONE IN PATIENTS WITH
H.I.V./AIDS
Serrano D1, Badia X1,
Álvarez Sanz C2, García Pulgar M3, Green J4
1Health Outcomes Research Europe Group, Barcelona, Cataluña,
Spain; 2 Roche Farma S.A, Madrid, Spain; 3 Roche
Farma S.A, Madrid, Madrid, Spain; 4 Hoffmann-La Roche Inc,
Nutley, NJ, USA |
|
|
PIN18 |
|
DETERMINANTS OF HEALTH CARE COSTS IN AMBULATORY
PATIENTS LIVING WITH HIV/AIDS
Lopez-Bastida J1, Oliva Moreno J2,
Perestelo Perez L1, Serrano Aguilar P1
1Canarias Health Service, Santa Cruz de Tenerife, Canary
Islands, Spain; 2 University Carlos III of Madrid, Getafe,
Madrid, Spain |
|
|
PIN19 |
|
INCORPORATING COMPLIANCE RATES INTO THE COST OF
TREATING HIV/AIDS IN TWO AFRICAN COUNTRIES
Becker RV, Benner J
ValueMedics Research, LLC, Falls Church, VA, USA |
|
|
PIN20 |
|
STUDY VALIDATION OF QUALITY OF LIFE QUESTIONNAIRE
MINI-HIV
Badia X, Perulero N, Roset M
Health Outcomes Research Europe, Barcelona, Spain |
|
|
PIN21 |
|
SELF ASSESSED HEALTH-RELATED QUALITY OF LIFE AMONG
HIV PATIENT IN UK
Shafie AA1, Salek S1, Evans RH2,
Freedman AR2, Birley H3, Browning M3,
Cohen D4
1Cardiff University, Cardiff, Wales, United Kingdom; 2
University Hospital of Wales, Cardiff, Wales, United Kingdom; 3
Cardiff Royal Infirmary, Cardiff, Wales, United Kingdom; 4
University of Glamorgan, Pontypridd, Wales, United Kingdom |
|
|
PIN22 |
|
COST-UTILITY ANALYSIS OF A HYPOTHETICAL VACCINATION
PROGRAM AMONG THE CURRENTLY TARGETED POPULATION IN THE NETHERLANDS IN
CASE OF AN INFLUENZA PANDEMIC
Meijboom M1, Buskens E1, Li-McLeod J2
1PharMerit, Rotterdam, Netherlands; 2 Baxter
BioScience, Westlake Village, CA, USA |
|
|
PIN23 |
|
COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE
UNITED KINGDOM
Nuijten MJ1, Lebmeier M2, Wittenberg W3
1MEDTAP International, Jisp, Netherlands; 2
University of Sheffield, Sheffield, United Kingdom; 3
Department Health Economics and Outcomes Research, Ludwigshafen, Germany |
|
|
PIN24 |
|
ADDING A QUADRIVALENT (6, 11, 16 & 18 TYPES) HUMAN
PAPILLOMAVIRUS VACCINE TO THE EXISTING UK CERVICAL SCREENING PROGRAMME IS
POTENTIALLY COST-EFFECTIVE
Kulasingam S1, Benard S2, Barnabas R3,
Myers E1
1Duke University, Durham, NC, USA; 2 Sanofi Pasteur
MSD, Lyon, France; 3 Cancer Research UK, Oxford, United
Kingdom |
|
|
PIN25 |
|
PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF A
POTENTIAL PROPHYLACTIC STHAPHYLOCOCCUS AUREUS VACCINE (STAPHVAX) IN
HEMODIALYSIS PATIENTS IN GERMANY
Staginnus U1, Russell S2
1Premor Associates, New York, NY, USA; 2 Premor
Associates, Madrid, Spain |
|
|
PIN26 |
|
COST-EFFECTIVENESS OF PREVENTING OF RECURRENT UPPER
RESPIRATORY TRACT INFECTIONS WITH NON-SPECIFIC IMMUNOSTIMULATING
BACTERIAL EXTRACT
Zaniolo O1, Pradelli L1, Eandi M2
1Advanced Research Srl, Torino, Italy; 2 University
of Turin, Torino, Italy |
|
|
PIN27 |
|
COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND
LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF INVASIVE CANDIDA AND
ASPERGILLOSIS INFECTIONS IN SPAIN
Aguado JM1, Díaz C1,
González P2, Fernández I2, Viudes A2
1Hospital Universitario 12 de Octubre, Madrid, Spain; 2
Pfizer S.A., Spain, Alcobendas, Madrid, Spain |
|
|
PIN28 |
|
RESOURCE USE AND COSTS ASSOCIATED WITH THE
MANAGEMENT OF PAP III, PAP IIID AND PAP IV IN THE PRE-HPV VACCINE ERA IN
GERMANY
Petry KU1, Hillemanns P2, Germé M3,
Littlewood KJ3, Benard S4, Breugelmans JG4
1Frauenklinik im Klinikum der Stadt Wolfsburg, Wolfsburg,
Germany; 2 Klinik für Frauenheilkunde und Geburtshilfe
Friedrich-Schiller Universität Jena, Jena, Germany; 3 Mapi
Values, Houten, Netherlands; 4 Sanofi Pasteur MSD | | |
